摘要
目的分析血管内皮生长因子-D(VEGF-D)、P-糖蛋白(P-gp)及P15蛋白在脑胶质瘤患者中的表达及与临床病理特征和预后的相关性。方法回顾性分析2017年1月—2019年2月收治的脑胶质瘤患者69例的临床资料。比较瘤组织和正常组织VEGF-D、P-gp及P15蛋白表达情况,分析VEGF-D、P-gp及P15蛋白与患者临床病理特征、预后的相关性。结果69例瘤组织中VEGF-D、P-gp阳性表达率高于正常组织,P15蛋白阳性表达率低于正常组织,差异有统计学意义(P<0.01);VEGF-D、P-gp及P15蛋白表达与肿瘤病理分级、分化程度有明显相关性(P<0.05或P<0.01)。年龄>45岁、病理分级Ⅲ~Ⅳ级、VEGF-D阳性表达、P-gp阳性表达、P15蛋白阴性表达及分化程度低为影响脑胶质瘤患者预后不良的独立危险因素(P<0.05或P<0.01)。结论VEGF-D、P-gp在脑胶质瘤患者中表达增加,P15蛋白表达降低,三者表达情况变化可为患者治疗方案制定、预后评估提供重要的参考。
Objective To analyze the expression of vascular endothelial growth factor-D(VEGF-D),P-glycoprotein(P-gp)and P15 protein in patients with glioma and its correlation with clinicopathological characteristics and prognosis.Methods The clinical data of 69 patients with glioma treated from January 2017 to February 2019 were retrospectively analyzed.The expressions of VEGF-D,P-gp and P15 protein between tumor tissue and normal tissue were compared,and the correlations of VEGF-D,P-gp and P15 protein with clinicopathological characteristics and prognosis of patients were analyzed.Results The positive expression rate of VEGF-D and P-gp in tumor tissue of 69 patients was higher than that in normal tissue,while the positive expression rate of P15 was significantly lower than that in normal tissue(P<0.01).The expression of VEGF-D,P-gp and P15 protein was significantly correlated with tumor pathological grade and degree of differentiation(P<0.05 or P<0.01).Age>45 years,pathological gradeⅢ-Ⅳ,positive VEGF-D expression,P-gp positive expression,P15 negative expression,and poor differentiation were independent risk factors that affected the prognosis of patients with glioma(P<0.05 or P<0.01).Conclusion The expression of VEGF-D and P-gp was increased in patients with glioma,and P15 expression was decreased.The changes in the expression of the three can provide important reference for the formulation of the patient's treatment plan and prognosis evaluation.
作者
向斌
杜军
张维波
刘盛
XIANG Bin;DU Jun;ZHANG Wei-bo;LIU Sheng(Department of Neurosurgery,Qianjiang Central Hospital,Chongqing 409000,China)
出处
《解放军医药杂志》
CAS
2021年第3期30-33,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
黔江区科技计划项目(黔科计2017080)。
